Exploring the use of Yunnan Baiyao for treating diabetic foot
Clinical Efficacy Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot
This study tests if Yunnan Baiyao, a traditional Chinese medicine, can help treat diabetic foot wounds and figure out the best ways to use it.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06062576 on ClinicalTrials.gov |
What this trial studies
This study investigates the efficacy of Yunnan Baiyao, a traditional Chinese medicine, in treating diabetic foot at various stages. It aims to clarify the best application methods and indications for this treatment by analyzing discarded tissues from patients undergoing wound debridement. The study will utilize transcriptome analysis to identify significant signal pathways and functional genes related to the treatment, providing evidence-based insights into its clinical efficacy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-80 diagnosed with diabetes and diabetic foot at specific stages of infection and granulation.
Not a fit: Patients with severe uncontrolled diabetes, active bleeding, or other serious health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment options for patients with diabetic foot, potentially improving healing outcomes.
How similar studies have performed: While Yunnan Baiyao has a long history of use, this study's approach to systematically evaluate its efficacy in diabetic foot is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The age of the subjects is 18-80 years old; 2. Diagnose diabetes according to WHO standards; 3. Diagnosis of Diabetic foot; 4. Confirmed as one of the stages of infection progression and granulation growth; 5. Voluntarily participate in this study and sign an informed consent form. Exclusion Criteria: 1. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet; 2. Blood glucose is out of control, Glucose test#Fasting blood sugar\>15mmol /L, Glycated hemoglobin\>12%; 3. There is active bleeding inside the wound, and routine basic treatment plans cannot be implemented; 4. Serum albumin\<20g/L; Hemoglobin\<60g/L; Platelets\<50 × 109/L; 5. Late stage subjects with malignant tumors; 6. Active period of autoimmune diseases; 7. Have a history of allergy to Yunnan Baiyao; 8. The subject is unable to cooperate or has mental disorders; 9. According to the judgment of the researcher, the subject has a clear reason that cannot be removed and affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.
Where this trial is running
Beijing, Beijing Municipality
- Peking University 3rd Hospital — Beijing, Beijing Municipality, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.